| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tofacitinib |
| Brand | Xeljanz® |
| Indication | For the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor). |
| Assessment Process | |
| Rapid review commissioned | 16/07/2018 |
| Rapid review completed | 18/09/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations November 2020.
